$208.62
-6.36(-2.96%)
Mkt Cap $368.9B
$170.16
$244.38
52-Week Range
At a Glance
AI-generatedAbbVie Inc.
Revenue breakdown: SKYRIZI (22.6%), HUMIRA (17%), RINVOQ (11.1%).
8-K
AbbVie discloses $744 million Q1 2026 acquired IPR&D and milestones expense, reducing both GAAP and adjusted diluted EPS by $0.41, with updated full-year 2026 adjusted EPS guidance of $13.96-$14.16.$368.9B
Market Cap
$60.7B
Revenue
$4.2B
Net Income
Employees55,000
Fundamentals
How The Business Makes Money
Revenue by Segment
SKYRIZI22.6%($74.1B)
HUMIRA17%($55.9B)
RINVOQ11.1%($36.5B)
Botox Therapeutic6.1%($20.1B)
Vraylar5.9%($19.3B)
Imbruvica5.2%($17.0B)
Botox Cosmetic4.9%($16.0B)
VENCLEXTA4.7%($15.3B)
Other Products2.7%($8.7B)
MAVYRET2.5%($8.1B)
Other Aesthetics2.3%($7.6B)
Juvederm Collection2.2%($7.1B)
Other Eye Care2%($6.6B)
Ubrelvy1.9%($6.2B)
Linzess Constella1.8%($5.9B)
Qulipta1.3%($4.2B)
Creon1.3%($4.2B)
Ozurdex0.9%($2.9B)
Duodopa0.8%($2.6B)
Lumigan Ganfort0.8%($2.5B)
Elahere0.7%($2.3B)
Other Neuroscience0.4%($1.4B)
Alphagan Combigan0.4%($1.4B)
Vyalev0.4%($1.2B)
Epkinly0.2%($569M)
Other Oncology0%($33M)
Revenue by Geography
US77.3%($256.6B)
Non Us10.6%($35.1B)
Other Countries4.9%($16.3B)
DE1.3%($4.5B)
JP1%($3.4B)
CA1%($3.4B)
CN0.9%($2.9B)
FR0.7%($2.4B)
ES0.5%($1.6B)
IT0.5%($1.6B)
GB0.5%($1.6B)
AU0.4%($1.4B)
BR0.4%($1.4B)
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001551152
ISINUS00287Y1091
CUSIP00287Y109
Phone847 932 7900
Address1 North Waukegan Road, North Chicago, IL, 60064-6400, US
SEC EDGAR